Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | MGLL | Q99685 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882525 | 0.98 | ALDH1A1 (0.81) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11480252 | 0.98 | ALDH1A1 (0.81) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3077817 | 0.96 | SMN1; SMN2 (0.72) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8845129 | 0.93 | KMT2A (0.73) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11882343 | 0.92 | MGLL (0.72) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8845496 | 0.91 | ALDH1A1 (0.77) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5653225 | 0.91 | ALDH1A1 (0.77) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5650832 | 0.88 | KMT2A (1.00) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27780514 | 0.86 | MGLL (0.66) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8468215 | 0.85 | GAA (0.63) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661017-B | Bicyclic or tricyclic heterocyclic compounds | 田边三菱制药株式会社 | 2019-09-24 | — | — | CN | claimed |
| EP-1034164-A4 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | claimed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | claimed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | claimed |
| JP-4295426-A | — | — | None | — | — | JP | disclosed |
| CN-109476709-B | Methods and compositions for conferring and/or enhancing herbicide tolerance using protoporphyrinogen oxidase or variants thereof | FARMHANNONG Co.,Ltd. (KR) | 2026-05-26 | — | — | CN | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| CN-111712567-B | Compositions and methods for conferring and/or enhancing herbicide tolerance using protoporphyrinogen IX oxidase variants from cyanobacteria | 福阿母韩农株式会社 | 2023-08-15 | — | — | CN | disclosed |
| US-20230175004-A1 | METHODS AND COMPOSITIONS FOR CONFERRING AND/OR ENHANCING HERBICIDE TOLERANCE USING PROTOPORPHYRINOGEN IX OXIDASE OF VARIOUS CYANOBACTERIA OR VARIANT THEREOF | Farmhannong Co., Ltd. (KR) | 2023-06-08 | — | — | US | disclosed |
| CN-116064434-A | Protoporphyrinogen oxidase variants | 福阿母韩农株式会社 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-4853470-A | 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-08-01 | — | — | US | disclosed |
| US-4806649-A | ANTIDEPRESSANTS, ANTICONVULSANTS, ANALGESICS, HYPOTENSIVE AGENTS, ANTIHALLUCINOGENS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4775761-A | TREATING PSYCHOSES, DEPRESSION, CONVULSIONS AND HYPERTENSION | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-10-04 | — | — | US | disclosed |
| US-4758668-A | 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-07-19 | — | — | US | disclosed |
| US-4710573-A | PSYCHOLOGICAL DISORDERS | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1987-12-01 | — | — | US | disclosed |
| US-4670447-A | ANALGESICS, ANTIDEPRESSANTS, ANTICONVULSANTS AND HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0135781-A1 | 3-(Piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles, a process for their preparation and their use as a medicament | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4234484-A | FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | ALDH1A1 4088/4885POLB 4764/4885SMN1; SMN2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.